Official Title
Expanded Access to Venetoclax
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available
Individual Patients
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Amyloidosis

Drug: Venetoclax
Venetoclax will be administered orally.
Other Name: ABT-199
Other Name: GDC-0199

Eligibility Criteria

Inclusion Criteria:

- The participant must not be eligible for a venetoclax clinical trial.

- Pediatric participants may be evaluated on a case by case basis.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Contacts

ABBVIE CALL CENTER
847.283.8955
abbvieclinicaltrials@abbvie.com

AbbVie Inc.
Study Director
AbbVie

NCT Number
Keywords
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Leukemia
Leukemia, Myeloid, Acute
Multiple Myeloma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Amyloidosis
Venetoclax